- Current report filing (8-K)
August 25 2010 - 5:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
August 25, 2010
(August 24, 2010)
ALLOS
THERAPEUTICS, INC.
(Exact name of registrant
as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
11080 CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrants
telephone number, including area code:
(303)
426-6262
Not applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 5.02.
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
(b)
James
V. Caruso, Executive Vice President and Chief Commercial Officer, departed
Allos Therapeutics, Inc. (Allos) effective Tuesday, August 24,
2010.
Item 7.01 Regulation FD
Disclosure.
Effective Tuesday, August
24, 2010, Allos promoted Michael Schick to Vice President, Sales and Marketing,
reporting to Paul Berns, President and Chief Executive Officer. In his new expanded role, Mr. Schick will be
responsible for leading Allos sales and marketing activities for FOLOTYN®
(pralatrexate injection).
Mr. Schick has served as
Vice President of Marketing of Allos since August 2009. Prior to joining Allos, Mr. Schick served as
Associate Vice President, Oncology Marketing at ImClone Systems from October
2007 to July 2009, where he was responsible for the Erbitux® (cetuximab injection)
franchise across multiple indications.
From February 2006 to October 2007, Mr. Schick was Executive Director,
Oncology Global Marketing at Amgen Inc., where he was responsible for marketing
Neulasta® (pegfilgrastim) and Aranesp (darbepoetin alfa injection). From November 2004 to January 2006, Mr.
Schick served as Director, Marketing, Oncology at Pharmacyclics, Inc. Prior to that, Mr. Schick served in a variety
of commercial roles at Bristol Myers Squibb, including sales, strategic
planning and product management focused on multiple brands including Taxol®
(paclitaxel injection) and Paraplatin® (carboplatin for injection). Mr. Schick earned a Bachelor of Arts degree
from Villanova University.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated:
August 25, 2010
|
|
ALLOS
THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/
Marc H. Graboyes
|
|
|
Marc
H. Graboyes
|
|
Its:
|
Senior
Vice President, General Counsel
|
3
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024